Skip to content
★ Sign in to follow
JR

Joshua R. Disbrow

Board Director
Director
Zynex IncAytu Biopharma, Inc
Insider activity · 24 months2 buys0 salesCumulative net flow
Total declarations
34
Companies
2
▲ Purchases (12 ops.)
€790k
▼ Sales (0 ops.)
—

Latest filing published 30 Jul 2026 for Aytu Biopharma, INC.

Filing timeline

BuySale
Joshua R. Disbrow

Insider track record

Disclosed buys
12
Disclosed sells
0
Signal history

Closed purchases

Market purchases
12
Positive at T+90
67%
Median T+90
+31.0%

Based on 6 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.

Purchases by company

Since each purchase

  • Filed 10 Jun 2025 · 516 days ago · €88k
    +13.5%
    Entry US$1.93 · Close at T+365 US$2.19
  • Filed 03 Mar 2025 · 615 days ago · €19k
    +107.1%
    Entry US$1.26 · Close at T+365 US$2.61
  • Filed 15 Jun 2023 · 1242 days ago · €24k
    +54.4%
    Entry US$1.82 · Close at T+365 US$2.81
  • Filed 21 Dec 2022 · 1418 days ago · €24k
    -30.7%
    Entry US$4.20 · Close at T+365 US$2.91
  • Filed 19 Dec 2019 · 2516 days ago · €40k
    -28.5%
    Entry US$172.00 · Close at T+365 US$123.00

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

Joshua R. Disbrow: trading record in brief

Joshua R. Disbrow, listed as board member, has filed trades across 2 companies (mainly through SEC (Form 4)), most often in Aytu Biopharma, Inc and Zynex Inc. Over a trading history stretching from 20 January 2016 to 28 July 2026, the count stands at 34 filings.

Purchases make up the whole of the open-market record (12 purchases, €790k). Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Outside the open market, there are 18 share grants and 1 option exercise.

A typical purchase (the median) is worth €52k. 6 out of 11 purchases came within 30 days of a purchase by at least one other insider of the same company. Purchases made close together by different insiders form what is called a cluster. After 6 purchases with a full 90-day history, the hit rate stands at 67% and the median 90-day move at +31.0%. These figures describe past trades and do not predict future prices.

The latest filing, published on 30 July 2026, reports a share grant in Aytu Biopharma, Inc. The clock since the last published purchase (10 June 2025) now reads 516 days. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.

Companies and markets linked to Joshua R. Disbrow

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Declarations29 total
  • ◆
    Chief Executive OfficerExecutivesAytu Biopharma, Inc
    0SEC
    30,000 shares0Common StockSEC:0001437749-26-025083:0
  • ●
    DirectorExecutivesZynex Inc
    0SEC
    89,501 shares0Common StockSEC:0001566240-26-000002:1
  • ●
    DirectorExecutivesZynex Inc
    0SEC
    12,499 shares0Common Stock (Restricted Stock Award)SEC:0001566240-26-000002:0
  • ◆
    Chief Executive OfficerExecutivesAytu Biopharma, Inc
    0SEC
    31,446 shares0Common StockSEC:0001437749-25-030642:0
  • ◆
    Chief Executive OfficerExecutivesAytu Biopharma, Inc
    0SEC
    22,500 shares0Common StockSEC:0001437749-25-030642:1
  • ▲
    Chief Executive OfficerExecutivesAytu Biopharma, Inc
    99,999 USD40SEC
    66,666 shares@ US$1.5042.7% of flowCommon StockSEC:0001437749-25-019956:0
    Canonical exit: 7 Sept 2025 (T+90)
  • ◆
    DirectorExecutivesZynex Inc
    0SEC
    10,000 shares0Common Stock (Restricted Stock Award)SEC:0001415889-25-013482:0
  • ▲
    Chief Executive OfficerExecutivesAytu Biopharma, Inc
    19,500 USD23SEC
    15,000 shares@ US$1.309.2% of flowCommon StockSEC:0001437749-25-005873:0
    Canonical exit: 29 May 2025 (T+90)
  • ▲
    DirectorExecutivesZynex Inc
    58,233 USD19SEC
    7,000 shares@ US$8.319100.0% of flowCommon StockSEC:0001415889-24-020376:0
    Canonical exit: 27 Oct 2024 (T+90)
  • ◆
    DirectorExecutivesZynex Inc
    0SEC
    10,000 shares0Common Stock (Restricted Stock Award)SEC:0001415889-24-013558:0
  • ◆
    DirectorExecutivesZynex Inc
    0SEC
    10,000 shares0Common Stock (Restricted Stock Award)SEC:0001104659-23-072360:0
  • ▲
    Chief Executive OfficerExecutivesAytu Biopharma, Inc
    26,079 USD25SEC
    14,000 shares@ US$1.862811.7% of flowCommon SharesSEC:0000912282-23-000133:0
    Canonical exit: 12 Sept 2023 (T+90)
  • ●
    Chief Executive OfficerExecutivesAytu Biopharma, Inc
    0SEC
    80,000 shares0Common StockSEC:0001567619-22-021999:0
  • ▲
    Chief Executive OfficerExecutivesAytu Biopharma, Inc
    25,048 USD35SEC
    112,371 shares@ US$0.222911.6% of flowCommon StockSEC:0001567619-22-021900:0
    Canonical exit: 19 Mar 2023 (T+90)
  • ◆
    Chief Executive OfficerExecutivesAytu Biopharma, Inc
    52,614 USD24SEC
    222,000 shares@ US$0.23724.8% of flowCommon SharesSEC:0001654954-22-015599:0
  • ◆
    DirectorExecutivesZynex Inc
    0SEC
    10,000 shares0Common Stock (Restricted Stock Award)SEC:0001104659-22-067713:0
  • ◆
    DirectorExecutivesZynex Inc
    0SEC
    10,000 shares0Common Stock (Restricted Stock Award)SEC:0001104659-21-093611:0
  • ◆
    Chief Executive OfficerExecutivesAytu Biopharma, Inc
    0SEC
    800,000 shares0Common StockSEC:0001567619-21-008228:0
  • ◆
    DirectorExecutivesZynex Inc
    0SEC
    10,000 shares0Common Stock (Restricted Stock Award)SEC:0001104659-20-088595:0
  • ◆
    DirectorExecutivesZynex Inc
    0SEC
    10,000 shares0Common Stock (Restricted Stock Award)SEC:0001104659-20-088595:1
  • ◆
    Chief Executive OfficerExecutivesAytu Biopharma, Inc
    0SEC
    450,000 sharesCommon stockSEC:0001654954-20-006583:0
  • ▲
    Chief Executive OfficerExecutivesAytu Biopharma, Inc
    44,370 USD23SEC
    50,000 shares@ US$0.887411.7% of flowCommon StockSEC:0001654954-19-014096:0
    Canonical exit: 18 Mar 2020 (T+90)
  • ▲
    Chief Executive OfficerExecutivesAytu Biopharma, Inc
    4,454 USD22SEC
    5,000 shares@ US$0.89081.2% of flowCommon StockSEC:0001654954-19-014096:1
    Canonical exit: 18 Mar 2020 (T+90)
  • ◆
    Chief Executive OfficerExecutivesAytu Biopharma, Inc
    0SEC
    445,500 sharesCommon StockSEC:0001213900-18-014532:0
  • ▲
    Chief Executive OfficerExecutivesAytu Biopharma, Inc

    Same trade as the filing by Jarrett Disbrow, counted once

    101,747 USD38SEC
    226,105 shares@ US$0.457.6% of flowCommon StockSEC:0001213900-18-002658:0
    Canonical exit: 4 Jun 2018 (T+90)

25 of 29 declarations